NCT07424781RecruitingNot Applicable
The Effect of Fluoxetine Treatment on Anger Processing in Healthy Young People
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- University of Oxford
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Behavioral Measure: Facial Expression Recognition Task (FERT)
Study Overview
Brief Summary
The goal of this clinical medicine study is to investigate how does antidepressant fluoxetine modulate anger processing in healthy young people . The main questions it aims is to answer are:
- How does fluoxetine affect responses to anger-related stimuli such as words, faces, and autobiographical recall?
- How does fluoxetine influence responses during frustration induction in frustrative non-reward and threat paradigms?
- Does the effect manifest in physiological markers, including heart rate variability and facial expressions?
Researchers will compare fluoxetine to a placebo to see if drug fluoxetine affects anger processing.
Participants will:
Take 20mg fluoxetine or a placebo every day for 7 days. Visit the university site for questionnaire and tasks assessments. Heart rate variability and facial expressions will be recorded in some of the tasks.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Basic Science
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 24 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Be aged 18-24 years (inclusive)
- •Be resident in the UK for the duration of the study
- •Have normal or corrected to normal vision
- •Participant is willing and able to give informed consent for participation in the research
- •Sufficiently fluent English to understand and complete the study
Exclusion Criteria
- •The participant may not enter the study if ANY of the following apply:
- •Psychiatric History:
- •Current or past diagnosis of any psychiatric disorder, as determined by the Structured Clinical Interview for the DSM-5 (SCID-5) and self-report. This includes, but is not limited to, depression, anxiety disorders, alcohol or drug dependency, personality disorders, suicidal ideation, and other psychiatric conditions;
- •First degree relative with a diagnosis of mania;
- •Heavy smoker or vaper (> 10 cigarettes per day, or >2 mL e-liquid, or >15mg/day from a nicotine patch);
- •Heavy use of caffeine (drink > 4 of 250ml cups/cans of coffee or energy drinks per day);
- •Heavy drinker (drink >14 standard alcoholic drinks per week);
- •Current or recent use (in the last 3 months) of any psychoactive substance according to self-report and a urine drug test screening for recent use of 10 common recreational substances;
- •Physical Health:
- •Severely underweight or overweight in a manner that renders them unsuitable for the study in the opinion of the study medical advisor;
- •Known contraindication to fluoxetine, such as hypersensitivity to fluoxetine or any component in its formulation;
- •Pregnancy, as determined by a urine pregnancy test or plans to become pregnant within the next 3 months;
- •Breastfeeding;
- •Not able to consume gelatine;
- •Medical History:
- •Past or ongoing health issue which, in the opinion of the study medical advisor, may interfere with the safety of the participant or the scientific integrity of the study, including but not limited to: seizures or epilepsy, heart rhythm problem, renal disease, hepatic disease, glaucoma, diabetes, bleeding disorders or clotting conditions (e.g., haemophilia, thrombocytopenia);
- •Diagnosis of a significant neurological condition (e.g., epilepsy, multiple sclerosis, traumatic brain injury).
- •Diagnosis of a neurodevelopmental condition, such as autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD);
- •Current or recent use of medication that might interfere or interact with the effects of fluoxetine, in the opinion of the study medical advisor, including but not limited to: monoamine oxidase inhibitors (MAOIs), medications affecting serotonin levels (e.g., tramadol, triptans, St. John's Wort), anticoagulants or blood thinners (e.g., warfarin), anti-inflammatory medications (e.g., aspirin, ibuprofen), or medications known to affect heart rhythm;
- •Prior Study Participation:
- •Participation in any other psychological or medical experiment involving taking any kind of drug/medication/vaccine, within the last 3 months;
- •Participation in any other study involving the current or similar tasks, within the last 6 months;
- •Any other significant finding which may arise during the screening process and which, in the opinion of the Principal Investigator/medical advisor, may influence the scientific integrity of the study, or the participant's ability to participate in the study.
Arms & Interventions
fluoxetine
Active Comparator
Participants will be taking 20mg fluoxetine daily.
Intervention: Fluoxetine (Drug)
placebo
Placebo Comparator
Participants will be taking one placebo capsule daily.
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Behavioral Measure: Facial Expression Recognition Task (FERT)
Time Frame: On the last day of the 7-day treatment
Recognition of angry faces in the Facial Expression Recognition Task
Secondary Outcomes
- Behavioural Measure: The Affordances Task(On the last day of the 7-day treatment)
- Behavioural Measure: Emotional Categorization Task (ECAT)(On the last day of the 7-day treatment.)
- Performance on Carnival Task(On the last day of the 7-day treatment.)
- Subjective Measure: Rest Task(On the last day of the 7-day treatment.)
- Subjective Measure: Anger Memory Recall Task(On the last day of the 7-day treatment.)
- Physiological Measure: Heart Rate Variability(On the last day of the 7-day treatment.)
- Physiological Measure: Facial Expression(On the last day of the 7-day treatment.)
- Behavioural measure: Emotional Recognition Memory Task (EMEM)(On the last day of the 7-day treatment.)
Investigators
Catherine Harmer
Professor of Cognitive Neuroscience
University of Oxford
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Evaluating the effect of Fluoxetine on symptoms and quality of life of patients with moderate to severe irritable bowel syndrome in adults.Irritable bowel syndrome.Irritable bowel syndromeIRCT138805012159N2Isfahan University of Medical Sciences180
Not yet recruiting
Unknown
The effectiveness of fluoxetine on the treatment of adaptive spasm caused by anxietyAccommodative spasm.Disorders of accommodationH52.5IRCT20240617062160N1Shahid Beheshti University of Medical Sciences68
Recruiting
Phase 4
ADAPT: Treatment of Agitated behaviour in patients with Dementia non-responsive to guideline recommended interventions by Argued Personalised Treatment using an N-of-1 approachDementia2024-510601-29-00Amsterdam UMC100
Not yet recruiting
Not Applicable
Role of Fluoxetine in Obsessive Compulsive Symptoms in SchizophreniaCTRI/2023/01/048718Government Medical College and Hospital Chandigarh
Withdrawn
Phase 3
EORTC 2237-BCG-QLG: Improvement of Quality of Life through supportive treatments for Endocrine Therapy – related symptoms in patients with early Breast cancer; A pragmatic randomized Controlled Trial (QOL-ET-BC)2024-513442-10-00Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi252